Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Amortizatization of Intangibles: 2016-2024

Historic Amortizatization of Intangibles for Cartesian Therapeutics (RNAC) over the last 9 years, with Dec 2024 value amounting to $2.4 million.

  • Cartesian Therapeutics' Amortizatization of Intangibles fell 70.60% to $192,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 44.96%. This contributed to the annual value of $2.4 million for FY2024, which is 38.94% up from last year.
  • Per Cartesian Therapeutics' latest filing, its Amortizatization of Intangibles stood at $2.4 million for FY2024, which was up 38.94% from $1.8 million recorded in FY2023.
  • In the past 5 years, Cartesian Therapeutics' Amortizatization of Intangibles ranged from a high of $2.4 million in FY2024 and a low of $1.1 million during FY2021.
  • Moreover, its 3-year median value for Amortizatization of Intangibles was $1.8 million (2023), whereas its average is $1.8 million.
  • As far as peak fluctuations go, Cartesian Therapeutics' Amortizatization of Intangibles declined by 13.37% in 2020, and later skyrocketed by 38.94% in 2024.
  • Over the past 5 years, Cartesian Therapeutics' Amortizatization of Intangibles (Yearly) stood at $1.1 million in 2020, then decreased by 0.71% to $1.1 million in 2021, then increased by 19.48% to $1.3 million in 2022, then soared by 31.19% to $1.8 million in 2023, then surged by 38.94% to $2.4 million in 2024.